A
Alcista
Alcista · 25%MLTX
$48.66
Precio del escenario
$10.260
+0.121 (+1.18%)Al cierre
Loading chart…
- Máximo
- 10.500
- Apertura
- 10.200
- Precio medio ponderado por volumen
- 10.32
- Volumen
- 1.07M
- Capitalización
- 2.62B
- Mínimo
- 10.190
- Importe
- 11.01M
- EV/EBITDA, TTM
- 0.00
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Análisis de IA of MoonLake Immunotherapeutics (MLTX)
MantenerMoonLake Immunotherapeutics is currently not a strong buy due to its high volatility and recent price decline, despite positive catalysts. The current price is $10.82, with a 5-day change of -5.17% and an RSI of 29.259 indicating oversold conditions. The company has a significant cash position of $537 million, which supports ongoing operations and clinical trials, but it also reported a substantial net loss of $69.7 million in Q1 2026, highlighting financial risks.
Métricas de valoración
El PER previsto actual de MoonLake Immunotherapeutics (MLTX) es 0.00, frente a su media de 5 años de -20.01.
Escenarios de precio de Alphio AI para MLTX
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con MLTX en cartera
Cronología de eventos
Noticias
9.009-11stocktwitsMoonLake Plans FDA Filing for Sonelokimab Approval
9.508-10stocktwitsMoonLake Reports Positive Phase 3 Results and Narrower Q2 Loss
8.508-03stocktwitsMoonLake Immunotherapeutics Investor Day Highlights
8.507-13stocktwitsMerck's Key Drug Faces Patent Cliff Ahead
5.007-03FoolCFO Sells 39,120 Shares of MoonLake Immunotherapeutics
Preguntas frecuentes sobre MLTX, respondidas por Alphio AI
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
MoonLake Immunotherapeutics is currently not a strong buy due to its high volatility and recent price decline, despite positive catalysts. The current price is $10.82, with a 5-day change of -5.17% and an RSI of 29.259 indicating oversold conditions. The company has a significant cash position of $537 million, which supports ongoing operations and clinical trials, but it also reported a substantial net loss of $69.7 million in Q1 2026, highlighting financial risks.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.